Activist investor Kaos Capital has issued a formal letter to Capricor Therapeutics, demanding an immediate meeting to address significant cash burn, governance issues, and a lack of strategic diversification. The firm intends to nominate independent directors and establish a committee to explore M&A and strategic alternatives, indicating a significant challenge to current management and strategy.
Kaos Capital's intervention signals a major challenge to Capricor Therapeutics' current management and strategy. The activist investor is concerned about the company's high cash burn, particularly the doubling of G&A expenses, and its over-reliance on a single asset (deramiocel), especially after a recent FDA panel rejection. This pressure could lead to significant changes in Capricor's board, operational strategy, and potentially M&A activities, creating short-term volatility and long-term uncertainty for shareholders. The immediate impact is negative, as evidenced by the stock price drop, due to the perceived instability and the underlying issues highlighted by Kaos Capital.